- Home
- CHRS vs ENX Comparison
CHRS vs ENX Comparison
Compare CHRS & ENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHRS
- ENX
- Stock Information
- Founded
- CHRS 2010
- ENX 2002
- Country
- CHRS United States
- ENX United States
- Employees
- CHRS N/A
- ENX N/A
- Industry
- CHRS Biotechnology: Biological Products (No Diagnostic Substances)
- ENX Finance/Investors Services
- Sector
- CHRS Health Care
- ENX Finance
- Exchange
- CHRS Nasdaq
- ENX Nasdaq
- Market Cap
- CHRS 159.2M
- ENX 169.0M
- IPO Year
- CHRS 2014
- ENX N/A
- Fundamental
- Price
- CHRS $1.35
- ENX $9.95
- Analyst Decision
- CHRS Strong Buy
- ENX
- Analyst Count
- CHRS 4
- ENX 0
- Target Price
- CHRS $4.51
- ENX N/A
- AVG Volume (30 Days)
- CHRS 1.2M
- ENX 25.4K
- Earning Date
- CHRS 11-05-2025
- ENX 01-01-0001
- Dividend Yield
- CHRS N/A
- ENX 3.94%
- EPS Growth
- CHRS N/A
- ENX N/A
- EPS
- CHRS 1.55
- ENX 0.16
- Revenue
- CHRS $272,209,000.00
- ENX N/A
- Revenue This Year
- CHRS N/A
- ENX N/A
- Revenue Next Year
- CHRS $109.48
- ENX N/A
- P/E Ratio
- CHRS $0.87
- ENX $61.00
- Revenue Growth
- CHRS 52.33
- ENX N/A
- 52 Week Low
- CHRS $0.66
- ENX $7.84
- 52 Week High
- CHRS $2.43
- ENX $10.07
- Technical
- Relative Strength Index (RSI)
- CHRS 64.99
- ENX 74.61
- Support Level
- CHRS $1.23
- ENX $9.38
- Resistance Level
- CHRS $1.40
- ENX $9.78
- Average True Range (ATR)
- CHRS 0.08
- ENX 0.09
- MACD
- CHRS -0.00
- ENX 0.04
- Stochastic Oscillator
- CHRS 72.13
- ENX 92.14
About CHRS Coherus BioSciences Inc.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both its pipeline candidates as well as its industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. Its portfolio includes LOQTORZI, CHS-114, and Casdozokitug.
About ENX Eaton Vance New York Municipal Bond Fund of Beneficial Interest $.01 par value
Eaton Vance New York Municipal Bond Fund is principally engaged in managing investment funds and providing investment management and advisory services to high-net-worth individuals and institutions. It is a non-diversified, closed-end investment company. Its objective is to provide current income exempt from regular federal income tax, including alternative minimum tax, and, in state specific funds, taxes in specified state.